«Some of our projects like Disney Infinity, Elder Scrolls Online, and Robot's Orcs Must Die 3 are coming to an end with
regards to the technology side and as such we have let some people go that were on those teams two weeks ago, which was roughly 18 folks, but we are still employing a good healthy company of around 50 people,» the representative said, in part.
These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related
to any of our products or products using our proprietary
technologies, which may lead
to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging
to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able
to continue
to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations
to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions
regarding the company's products; the company's products may prove difficult
to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended
side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
There is much more
to say about this, particularly as
regards the role of F3 in reducing dimension, but after spending a day writing some 25 paragraphs about filtering
technology and dimension reduction I realized I should instead organize it as a post and therefore put it
to one
side for the time being so I can respond more immediately
to other comments.